NIH Releases Phase 3 Results on New Vaccine

Johnson and Johnson’s one-dose vaccine “appears to be safe and effective.”

The National Institutes of Health within the U.S. Health and Human Services Department has announced that “investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data.”

Johnson & Johnson took longer than their counterparts in developing a COVID-19 vaccine, but the study released Friday showed one dose to be effective against up to 85% of severe COVID-19 symptoms. Another benefit of the new vaccine is that it can be kept in refrigeration storage rather than frozen, decreasing the possibility of spoilage. J&J is seeking emergency authorization to administer the vaccine in the U.S.

As the Lord Leads, Pray with Us…

  • For the United States as the hope of the end of the pandemic nears.
  • For the FDA in their considerations as J&J seek emergency authorization.
  • For researchers and scientists as they continue to develop treatments and mitigations for disease.

Sources: AP,


Back to top